Financial reports
10-Q
2024 Q1
Quarterly report
25 Apr 24
10-K
2023 FY
Annual report
1 Feb 24
ARS
2022 FY
Annual report to shareholders
19 Dec 23
10-Q
2023 Q3
Quarterly report
18 Oct 23
10-Q
2023 Q1
Quarterly report
21 Jul 23
10-Q
2023 Q1
Quarterly report
24 Apr 23
10-K
2022 FY
Annual report
24 Feb 23
10-Q
2022 Q3
Quarterly report
28 Oct 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
2 May 22
Current reports
8-K
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
25 Apr 24
8-K
Departure of Directors or Certain Officers
23 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
8-K
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
3 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
8-K
Departure of Directors or Certain Officers
6 Feb 24
8-K
ARCA biopharma Announces 2023 Financial Results
1 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
Registration and prospectus
425
Business combination disclosure
25 Apr 24
425
Business combination disclosure
3 Apr 24
424B5
Prospectus supplement for primary offering
18 Mar 22
424B5
Prospectus supplement for primary offering
6 Apr 21
RW
Registration withdrawal request
2 Apr 21
S-3
Shelf registration
22 Mar 21
S-8
Registration of securities for employees
17 Dec 20
424B5
Prospectus supplement for primary offering
22 Jul 20
424B5
Prospectus supplement for primary offering
14 Jul 20
424B5
Prospectus supplement for primary offering
2 Jul 20
Proxies
DEFA14A
Additional proxy soliciting materials
19 Dec 23
DEF 14A
Definitive proxy
19 Dec 23
DEFA14A
Additional proxy soliciting materials
3 Nov 22
DEF 14A
Definitive proxy
3 Nov 22
DEFA14A
Additional proxy soliciting materials
28 Jun 21
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
DEFA14A
Additional proxy soliciting materials
9 Dec 20
DEFA14A
Additional proxy soliciting materials
28 Oct 20
DEF 14A
Definitive proxy
28 Oct 20
Other
EFFECT
Notice of effectiveness
31 Mar 21
UPLOAD
Letter from SEC
26 Mar 21
CORRESP
Correspondence with SEC
26 Mar 21
EFFECT
Notice of effectiveness
21 May 20
CORRESP
Correspondence with SEC
18 May 20
UPLOAD
Letter from SEC
14 May 20
CT ORDER
Confidential treatment order
17 May 19
CT ORDER
Confidential treatment order
10 May 18
CT ORDER
Confidential treatment order
13 Dec 17
EFFECT
Notice of effectiveness
12 May 17
Ownership
SC 13G
Allostery Investments LP
15 Apr 24
SC 13G
JANUS HENDERSON GROUP PLC
11 Apr 24
SC 13G
Avidity Partners Management LP
9 Apr 24
SC 13G/A
Western Standard LLC
5 Apr 24
SC 13D
Adage Capital Management, L.P.
5 Apr 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Jacob Ma-Weaver
31 Jan 24
4
Anders D Hove
31 Jan 24
4
DANIEL J MITCHELL
31 Jan 24
4
James P Flynn
31 Jan 24